Comparative Pharmacology
Head-to-head clinical analysis: FLAVOXATE HYDROCHLORIDE versus URISPAS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAVOXATE HYDROCHLORIDE versus URISPAS.
FLAVOXATE HYDROCHLORIDE vs URISPAS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Flavoxate hydrochloride is a smooth muscle relaxant with anticholinergic and local anesthetic properties. Its mechanism of action involves direct inhibition of smooth muscle contraction in the urinary tract, reducing detrusor muscle spasm, and decreasing urinary frequency and urgency.
Urispas (flavoxate) is a smooth muscle relaxant that exerts a direct spasmolytic effect on the detrusor muscle of the urinary bladder. It has anticholinergic, local anesthetic, and analgesic properties, but its exact mechanism is not fully understood.
100-200 mg orally 3-4 times daily; maximum 800 mg/day.
20 mg orally three times daily.
None Documented
None Documented
Approximately 3-4 hours; clinical context: short half-life supports multiple daily dosing in overactive bladder therapy.
Terminal elimination half-life is approximately 2-3 hours in healthy adults; may be prolonged in renal impairment (creatinine clearance <30 mL/min extends half-life to 5-7 hours).
Renal: approximately 30-60% of an oral dose is excreted unchanged in urine; the remainder is metabolized and eliminated via bile and feces.
Primarily renal (approximately 50-70% as unchanged drug and metabolites); minor biliary/fecal elimination (<10%).
Category C
Category C
Urinary Antispasmodic
Urinary Antispasmodic